PET-based dosimetry aids in delivery of radiolabeled antibodies

04/22/2012 | MolecularImaging.net

Individualized PET/CT-based bone marrow dosimetry may be a more accurate tool than plasma-based dosimetry in the delivery of therapeutic radiolabeled antibodies in cancer patients, according to a study published in the Journal of Nuclear Medicine, in some cases allowing for higher doses of the therapeutic agent. The researchers used two 124I-labeled antibodies, cG250 and huA33.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC